News & Blog

Monthly Archives: December 2021

Widely-available Drug May Benefit Glioblastoma Treatment

Based on data from NBTS’s Defeat GBM Research Collaborative and with support from the Sharpe family, Dr. Paul Mischel (Stanford University) and his laboratory team found that the antidepressant drug, fluoxetine (common brand name: Prozac), potently targets tumor metabolism and inhibits epidermal growth factor (EGFR) signaling, triggering the killing of glioblastoma (GBM) cells. Dr. Mischel’s […]

Share